{{about|the drug|the electronic component|TRIAC|the car|Triac (car)}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470610738
| IUPAC_name = [4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
| image = Tiratricol.svg
| width = 240
| image2 = Tiratricol 3D ball.png
| alt2 = Ball-and-stick model of the tiratricol molecule
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|tiratricol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = Presumed high
| metabolism = [[Liver|Hepatic]] [[glucuronidation]]
| elimination_half-life =  
| excretion = Biliary

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 51-24-1
| ATC_prefix = H03
| ATC_suffix = AA04
| ATC_supplemental =  {{ATC|D11|AX08}}
| PubChem = 5803
| IUPHAR_ligand = 2637
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB03604
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5598
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 29OQ9EU4R1
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07214
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 41632

<!--Chemical data-->
| C=14 | H=9 | I=3 | O=4 
| molecular_weight = 621.932 g/mol
| smiles = Ic2cc(Oc1c(I)cc(cc1I)CC(=O)O)ccc2O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UOWZUVNAGUAEQC-UHFFFAOYSA-N
| synonyms = 3,3',5-triiodothyroacetic acid<br>TRIAC
}}
'''Tiratricol''' (also known as '''TRIAC''' or triiodothyroacetic acid) is a [[thyroid hormone]] [[analog (chemistry)|analogue]]. Triiodothyroacetic acid is also a physiologic [[thyroid hormone]] that is present in the normal organism in low concentrations.

==Uses==
It is indicated in the management of [[thyroid hormone resistance|thyroid hormone resistance syndrome]]<ref>{{cite journal |vauthors=Carvalho GA, Ramos HE |title=[Thyroid hormone resistance syndrome] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=48 |issue=1 |pages=83–92 |year=2004 |pmid=15611821 |doi=10.1590/S0004-27302004000100010}} {{cite web|url= http://www.scielo.br/pdf/abem/v48n1/19522.pdf |title=Free full text }}&nbsp;{{small|(95.3&nbsp;[[Kibibyte|KiB]])}}</ref> and is used, in combination with [[levothyroxine]], to suppress [[thyroid-stimulating hormone]] production in patients with [[thyroid cancer]].

It has been investigated for use in reducing [[goiter]].<ref name="pmid14602763">{{cite journal  |vauthors=Brenta G, Schnitman M, Fretes O, etal |title=Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=11 |pages=5287–92 |date=November 2003 |pmid=14602763 |doi= 10.1210/jc.2003-030095|url=http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=14602763}}</ref>

It has also shown some effectiveness in reducing the atrophy caused when using [[corticosteroid]]s.<ref name="pmid17123343">{{cite journal |vauthors=Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J |title=Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans |journal=Thyroid |volume=16 |issue=11 |pages=1157–62 |date=November 2006 |pmid=17123343 |doi=10.1089/thy.2006.16.1157}}</ref>

Tiratricol has also been widely marketed, under various trade names, as a [[weight loss]] aid. In 1999 and 2000, the United States [[Food and Drug Administration]] and [[Health Canada]] both issued warnings to the public regarding the use of [[dietary supplement]]s containing tiratricol.<ref>{{cite press release | url = http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html | title = FDA Warns Against Consuming Dietary Supplements Containing Tiratricol | date = November 21, 2000 | accessdate = 2007-08-08 | publisher = U.S. [[Food and Drug Administration]]}}</ref><ref>{{cite press release | url = http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html | title = Health Canada issues warning on products containing Tiratricol (TRIAC) | date = December 2, 1999 | accessdate = 2007-08-08 | publisher = [[Health Canada]]}}</ref>

==Legal status==
Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in [[Brazil]], but its marketing authorization was suspended in 2003, effectively prohibiting its sale.<ref>{{cite web | url = http://www.endocrino.org.br/noticia_g_exibe.php?id=9 | title = Anvisa suspende Tiratricol | language = Portuguese | date = | accessdate = 2007-08-08 | publisher = Brazilian Society of Endocrinology and Metabolism |archiveurl = https://web.archive.org/web/20071009062707/http://www.endocrino.org.br/noticia_g_exibe.php?id=9 <!-- Bot retrieved archive --> |archivedate = 2007-10-09}}</ref> Tiratricol is still available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer.<ref>Laboratoires DB PHARMA: [http://www.db-pharma.com/fiche.cfm?id=24 Teatrois] information</ref> It is available as an [[orphan drug]] to be prescribed by registered specialists in Europe.

==References==
{{Reflist|2}}

{{Other dermatological preparations}}
{{Thyroid therapy}}
{{Thyroid hormone receptor modulators}}
{{Thyroid hormone intermediates}}

[[Category:Orphan drugs]]
[[Category:Iodoarenes]]
[[Category:Phenols]]
[[Category:Phenol ethers]]


{{systemic-hormonal-drug-stub}}
{{dermatologic-drug-stub}}